OraSure Appoints AI Diagnostics Executive, Pursues Board Declassification via Altai Deal
OraSure named AI diagnostics veteran John D. Bertrand to its board as an independent director and agreed with Altai Capital to withdraw its proxy nominations. The company will seek shareholder approval to declassify its board at the 2026 annual meeting, reinforcing governance reforms after the agreement.
1. Appointment of John D. Bertrand
OraSure has added John D. Bertrand as an independent director, leveraging his decade of experience in AI-enabled diagnostics from leadership roles at Digital Diagnostics Inc., Epic Systems, Bain Capital and 8VC to bolster its strategic and commercial initiatives.
2. Board Declassification Proposal
The company intends to present a declassification proposal at its 2026 annual meeting, converting its classified board into one where all directors stand for annual election, aiming to enhance accountability and shareholder influence.
3. Cooperation Agreement with Altai Capital
Under a cooperation agreement, Altai Capital Management will withdraw its director nominations and engage regularly with OraSure’s board and management on financial and strategic matters, with customary standstill, voting and governance provisions.
4. Strategic Governance Impact
These moves are designed to resolve proxy contest uncertainty, strengthen governance practices and support OraSure’s multi-year transformation strategy to drive growth, margin improvement and long-term shareholder value.